Ipsen and GENFIT Announce Positive Results from Phase III EL

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placeboElafibranor was well tolerated with a safety profile

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , China , Paris , France General , France , Saclay , United States , Canada , Switzerland , Shanghai , French , American , Stephanie Boyer , Amy Wolf , Pascal Prigent , Howard Mayer , Anna Gibbins , Nicolas Bogler , Jean Christophe Marcoux , Ipsen Ipnipseyand , Ioana Piscociu , Nasdaq , European Medicines Agency , Head Of Corporate Brand Strategy Communications Tel , Exchange Commission , Development For Ipsen , Uncertainties Of The Company , Drug Administration , Global Head Of Franchise Communications , Head Of Research , Euronext , Corporate Affairs , Executive Vice President , Chief Executive Officer , Breakthrough Therapy , Rare Disease , Sponsored Leveli American Depositary Receipt , Nasdaq Global Select Market , French Autorit , Des March , Universal Registration Document , Private Securities Litigation Reform Act , Registration Document , Vice President , Investor Relations , Investor Relations Manager , Global Head , Franchise Communications , Senior Manager Global Media Relations , Corporate Brand Strategy , Christophe Marcoux , Chief Corporate Affairs Officer , Orphanetj Rare , Transplantation Hepatology ,